Clinical trial

A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.

NCT02576548

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2015-09-23

PhasePHASE1

Study timeline

Study start (actual)2015-09-23Date precision: day

Registry last updated2019-06-18

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HER2 Expressing Breast or Gastric/Stomach Cancersunresolved

Interventions

MEDI4276BIOLOGICAL

Sponsors & collaborators

MedImmune LLClead sponsor

Mapped research locations

NashvilleTennessee, United States1 IndianapolisIndiana, United States1 CharlotteNorth Carolina, United States1 StanfordCalifornia, United States1 SarasotaFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02576548 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.